ReviewNature reviews. Urology2019
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Review in Nature reviews. Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).The Journal of urology · 2023Trial
- Assembly-formed bioorthogonal chimeric artificial receptors enable high-contrast fluorescence imaging of tumors.Science advances · 2026Article
- Clinical fluorescent contrast agents for image-guided surgery.Fundamental research · 2026Review
- Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A Critical Review.Bioengineering (Basel, Switzerland) · 2025Review
- pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for Bladder Cancer-Associated microRNAs.ACS nano · 2025Article
- Ex Vivo Human Tissue Functions as a Testing Platform for the Evaluation of a Nerve-Specific Fluorophore.Molecular imaging and biology · 2025Article
- Systematic comparison of fluorescence imaging in the near-infrared and shortwave-infrared spectral range using clinical tumor samples containing cetuximab-IRDye800CW.Journal of biomedical optics · 2025Article
- Impact of signal-to-noise ratio and contrast definition on the sensitivity assessment and benchmarking of fluorescence molecular imaging systems.Journal of biomedical optics · 2025Article
- Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.Communications medicine · 2024Article
- Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024Review
- Progress of fluorescence imaging in lymph node dissection surgery for prostate and bladder cancer.Frontiers in oncology · 2024Review
- Targeted PLGA-Chitosan Nanoparticles for NIR-Triggered Phototherapy and Imaging of HER2-Positive Tumors.Pharmaceutics · 2023Article
- Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.European urology open science · 2023Article
- Efficient Augmented Intelligence Framework for Bladder Lesion Detection.JCO clinical cancer informatics · 2023Article
- The Evolution of Fluorescence-Guided Surgery.Molecular imaging and biology · 2023Review
- UrinaryCancers · 2023Article
- Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model.Bladder cancer (Amsterdam, Netherlands) · 2023Article
- Classification between Normal and Cancerous Human Urothelial Cells by Using Micro-Dimensional Electrochemical Impedance Spectroscopy Combined with Machine Learning.Sensors (Basel, Switzerland) · 2022Article
- The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer.Current urology · 2022Article
- Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures.World journal of urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 19 institutions in 2 countries.
Funding
Abstract
Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.